Last reviewed · How we verify
NCT06060808
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
trial testing gene polymorphism in Liver Transplant Rejection in 105 participants. Completed in 24 July 2023.
23 April 2023
Quick facts
| Lead sponsor | Helwan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 15 March 2021 |
| Primary completion | 23 April 2023 |
| Estimated completion | 24 July 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- gene polymorphism
Conditions studied
- Liver Transplant Rejection — all drugs for Liver Transplant Rejection →
Sponsor
Helwan University
Who can join
Adults 20 to 64, any sex, with Liver Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our study aimed at studying the impact of gene polymorphism of NFKBIA and PTPN22 genes on rejection episodes in liver transplant Egyptian recipients. Also assess patients' factors associated with graft rejection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06060808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Transplant Rejection
Currently open trials in the same condition.
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
- NCT06400771 — Safety of DNP007 in Healthy Subjects · Phase 1 · recruiting
- NCT05325073 — Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients · Phase 4 · active not recruiting
- NCT06153641 — Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients · active not recruiting
Other Helwan University trials
Trials by the same sponsor.
- NCT07342361 — Using Retrograde Intrarenal Surgery for Managing Staghorn Renal Stones. · NA · recruiting
- NCT06786507 — A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis · not yet recruiting
- NCT06535529 — Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients · Phase 3 · recruiting
- NCT07416331 — Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Rep · completed
- NCT06884995 — Correlation of Weight Loss With Residual Gastric Volume and Shape on Computerized Tomography in Patients Undergoing Slee · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06060808 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helwan University
- Last refreshed: 29 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing